As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...

Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, ...

Novavax (NVAX) announced preliminary results from the SHIELD-Utah study that showed Novavax’s COVID-19 Vaccine, Adjuvanted 2024-2025 Formula ...

Shares of Novavax, Inc. (NVAX) plunged over 19.5% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr.

Complex Pandemic Accord negotiations have been underway since 2021, with 13 formal meetings and numerous informal sessions.

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

An advisory panel on vaccines meets, carefully, in the shadow of a health secretary who has often criticized it.

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.